Benitec Biopharma Inc. BNTC
Set alert
8.62 USD +0.13 +1.47%
As of Nov 3, 10:24 AM ET
8.51 Day range 8.89
8.11 52-week range 15.86
- YTD
- -36.04%
- 1 year
- -45.68%
- Open
- 8.58
- Prev close
- 8.49
- Mkt cap
- 300.57M
- Vol
- 6.48K
- Avg vol
- 179.66K
- EPS
- -0.98
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.51
- High
- 8.89
- Forward P/E
- -1.23
- Beta
- 0.88
- Short ratio
- 1.35
- Inst. own
- 82.59%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 11, 2025
- 50-d avg
- 10.82
- 200-d avg
- 8.69
- 1y target
- 25.43
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 25.43 +195.2% upside
Now 8.62
- Target (low)
- 17.00
- Target (mean)
- 25.43
- Target (high)
- 35.00
Ratings (0m) 7 7 buy · 0 hold · 0 sell
- Strong buy3
- Buy4
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 5
- 2 months ago 5
- 3 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.39 | -0.39 – -0.39 | 0.00 | 0.0% | 0 | 0.0% | 1 |
| Next quarter | -0.42 | -0.42 – -0.42 | 0.00 | 0.0% | 0 | 0.0% | 1 |
| Current year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Next year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 13, 2024 | Baird | Initiated | — | Outperform |
| Dec 3, 2024 | Guggenheim | Reiterated | Buy | Buy |
| Jul 22, 2024 | Leerink Partners | Initiated | — | Outperform |
| Jun 13, 2024 | Piper Sandler | Initiated | — | Overweight |
| Apr 22, 2024 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| Feb 15, 2024 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| Jan 24, 2024 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| Sep 26, 2023 | JMP Securities | Maintained | Market Outperform | Market Outperform |